Brokers Issue New Targets On Novavax, Inc. (NASDAQ:NVAX)

Ivan Schwartz
May 20, 2017

Brokerage houses, on average, are recommending investors to hold Novavax, Inc.

The share price of the company (NASDAQ:NVAX) was down -8.85%, with a high of 1.11 during the day and the volume of Novavax, Inc. shares traded was 7489603. The stock has earnings growth of 1.00% yoy and showed a high EPS growth of 11.20% over the past five years.

NVAX offered -43.40% EPS for prior five years and the earnings per share (EPS) growth projected to be -72.80% in the coming year. The firm is expected to report its next quarterly earnings results on Wednesday, May 3rd.

Novavax, Inc. (NVAX) stock price fell -78.76 percent over the past one year, while decreased -20.16 percent during the past 6 months. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report -0.16 earnings per share. The mean target projections are based on 6 opinions.

Novavax, Inc. (NVAX) belongs to the "Healthcare" sector with an industry focus on "Biotechnology", with Mr. Stanley Charles Erck as Chief Exec. Officer, Pres and Director. Sometimes, companies with strong fundamentals but with low annualized EPS of less than 4 or 5 % but analysts may talk about a huge turnaround in the earnings due to heavy order book. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%.

The company's revenue in the quarter amounted to $5.7 million which is a 35% increase from the $4.2 that was reported in the same period in 2016.

While trading at volume above than average, The Dow Chemical Company (NYSE:DOW) previous 52-week high was $64.96 and moved up 20.79% over the same period, trading at a volume of 7.34 million. Novavax's quarterly revenue was up 34.6% on a year-over-year basis.

Key moments of Trump-Comey clash and what's come after
CNN reported Friday that Comey is "not worried" about Trump's suggestion that their conversations could have been recorded. May 2, 2017: Clinton again lays part of the blame for losing the election on Comey's October 28 letter.

G7 commit to tackling cyber attacks
Greece's creditors, including the European Central Bank and the International Monetary Fund, will be in Bari . The meeting also coincided with news of a significant foray by the Trump administration into global commerce.

Pune beat Punjab to seal IPL play-off spot
Saurabh Tiwary also came good in his first game of the season but he is unlikely to find a place ahead of Nitish Rana. The hosts, who are also two-time league champions, finished on top of the table with 20 points from 14 games.

CONSOL Energy Inc. (CNX) exchanged hands at an unexpectedly low level of 2.83 million shares over the course of the day.

Volatility of the shares is also to be considered while making the investment decisions.

The stock increased +5.83% (+0.06) during the last days session, reaching 1.03 and roughly 4520269 shares were bought or sold by traders.

The number of shares now held by investors is 282.61 Million. FBR & Co restated an "outperform" rating and set a $12.00 price objective on shares of Novavax in a research note on Wednesday, January 18th. Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Price targets frequently change, depending on the outlook for a company's earnings. JPMorgan Chase & Co. boosted its stake in Novavax by 110.5% in the third quarter. The stock traded at a volume of 7.41 million shares.

11/10/2016 - Novavax, Inc. had its "neutral" rating reiterated by analysts at Wedbush. Piermont Capital Management Inc. now owns 158,788 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 13,370 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of Novavax during the third quarter valued at approximately $751,000. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company's stock worth $25,163,000 after buying an additional 9,947,481 shares during the last quarter.

At the close of the quarter, Novavax, Inc.

Market Capitalization can be thought of as the overall price to buy the company. Latest closing price was -2.85% below its 50-day moving average and -56.05% below its 200-day moving average.

Other reports by GizPress

Discuss This Article